Clinical Trials Logo

Clinical Trial Summary

The aim of the study is to demonstrate concordance (percent agreement) between results produced by the Spartan CYP2C19 system and bi-directional sequencing. In addition, this study will evaluate the concordance of buccal samples stored prior to running on the Spartan Cube CYP2C19 system and bi-directional sequencing.


Clinical Trial Description

Sample holding time - two parts

1. Sample tested in less than one-hour

a.In the first part, buccal samples will be collected from subjects and tested using the Spartan Cube CYP2C19 system. These samples will be run immediately (within 1 h) after collection from the subject (<1 h sample holding time). All results will be compared to bi-directional sequencing to determine percent agreement.

2. Sample tested greater than 21 hours a.In the second part (sample holding portion), samples will be tested using the Spartan Cube CYP2C19 product. These samples will be run after storage at ambient temperature. All results will be compared to bi-directional sequencing to determine the percent agreement. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04473586
Study type Interventional
Source Spartan Bioscience Inc.
Contact
Status Completed
Phase N/A
Start date February 5, 2020
Completion date March 6, 2020

See also
  Status Clinical Trial Phase
Completed NCT01718535 - Method Comparison Study of the Spartan FRX CYP2C19 Genotyping System Against Bi-directional Sequencing N/A
Completed NCT04473573 - Spartan Cube CYP2C19 Inter Laboratory Reproducibilty Study N/A